Evidence map›Paper›PMID 40667280›Full record

ArticlebioRxiv : the preprint server for biology2025

Integrated Spatial Analysis of Ovarian Precancerous Lesions.

Tu-Yung Chang, Yen-Wei Chien, Szu-Hua Chen, Annelise Sokolow, Yeh Wang, Brant G Wang, Tricia Numan, M Herman Chui, Rebecca Stone, Thomas Pisanic and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Tu-Yung ChangDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.ORCID 0009-0007-8589-7775
Yen-Wei ChienDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Szu-Hua ChenDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Annelise SokolowDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Yeh WangDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Brant G WangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Tricia NumanDepartment of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland.
M Herman ChuiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Rebecca StoneDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Thomas PisanicInstitute for Nanobiotechnology, Johns Hopkins University, Baltimore, Maryland.
Nicholas PapadopoulosSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Tian-Li WangDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Christopher DouvilleSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Leslie CopeSidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Ie-Ming ShihDepartment of Gynecology and Obstetrics, Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore, Maryland.

Funding

SPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Amanda Nickles Fader · 2018 to 2026
$20.5M
Biomarker Reference LaboratoryU2CCA271891 · NCI · JOHNS HOPKINS UNIVERSITY · PI ZHEN ZHANG · 2022 to 2026
$4.0M
Development of a low-cost epigenetic screening assay for Pap specimen-based detection of early-stage ovarian cancer in high-risk womenR01CA260628 · NCI · JOHNS HOPKINS UNIVERSITY · PI PISANIC II, THOMAS RUSSELL, SHIH, IE-MING · 2021 to 2025
$2.1M
Experimental Therapeutics by targeting Spleen Tyrosine KinaseR01CA215483 · NCI · JOHNS HOPKINS UNIVERSITY · PI SHIH, IE-MING · 2017 to 2021
$1.9M
NCI NIH HHS P50 CA228991NCI NIH HHS R01 CA215483NCI NIH HHS R01 CA260628NCI NIH HHS U2C CA271891
6 · The paper itself

Abstract

Studying precancerous lesions is essential for improving early detection and prevention, particularly in aggressive cancers such as ovarian carcinoma. Here, we conducted integrated and spatial analyses of transcriptomes, aneuploidy, and clinic-pathological features in 166 ovarian precancerous lesions. Four pre-cancerous subtypes were identified transcriptomically: proliferative, immunoreactive, dormant, and mixed. These subtypes varied in their frequency of germline-

Indexed as

BRCA1ovarian cancerprecursor lesions

Identifiers

PMID40667280
PMCPMC12262305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.